Related Experiment Video
Updated: May 2, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Drug therapy to reduce early readmission risk in heart failure: ready for prime time?
Muthiah Vaduganathan1, Gregg C Fonarow2, Mihai Gheorghiade3
1Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract:
Readmission for heart failure remains a major focus of policymakers, clinicians, and patients. Despite meeting key national performance measures and frequent use of evidence-based therapies, rates of 30-day post-discharge rehospitalization may be as high as 25%. Digoxin and mineralocorticoid antagonists are known to reduce admissions for heart failure, but are significantly underused in current clinical practice despite their proven benefits.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Coronary Syndrome IV: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: β-Blockers